Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Free Cash Flow (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Free Cash Flow data on record, last reported at $96.9 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 564.07% year-over-year to $96.9 million; the TTM value through Sep 2025 reached $145.3 million, up 345.78%, while the annual FY2024 figure was $41.9 million, 166.75% up from the prior year.
  • Free Cash Flow reached $96.9 million in Q3 2025 per GLUE's latest filing, up from -$33.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $129.0 million in Q4 2024 and bottomed at -$47.1 million in Q1 2025.
  • Average Free Cash Flow over 3 years is -$419454.5, with a median of -$27.0 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 40.78% in 2024, then surged 564.07% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at $27.9 million in 2023, then skyrocketed by 361.63% to $129.0 million in 2024, then dropped by 24.85% to $96.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $96.9 million in Q3 2025, -$33.6 million in Q2 2025, and -$47.1 million in Q1 2025.